Webinar | November 7, 2019

How to Ensure Biosafety Of Novel Viral Therapies

Novel viral therapies are emerging and gaining more interest after recent regulatory approval of CAR-T and AAV based gene therapies. While no viral contamination has been reported so far for these therapies, it is important to learn from historical experience and leverage improved manufacturing and testing methods to increase their safety. This would help avoid product supply and patient treatment disruptions as well as protect the company’s business and reputation. In this webinar we will highlight the biosafety challenges associated with the manufacture of viral vectors and how a holistic risk mitigation approach can reduce contamination events.

In this webinar, you will learn:

  • Lessons learned from prior contaminations
  • How improvements in manufacturing and testing have reduced risk
  • How to identify viral safety risk areas
VIEW THE WEBINAR!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of BioProcess Online? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
I'm interested in newsletter subscriptions.
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: